These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 29507106)

  • 1. The Immunogenicity of a Proline-Substituted Altered Peptide Ligand toward the Cancer-Associated TEIPP Neoepitope Trh4 Is Unrelated to Complex Stability.
    Hafstrand I; Doorduijn EM; Sun R; Talyzina A; Sluijter M; Pellegrino S; Sandalova T; Duru AD; van Hall T; Achour A
    J Immunol; 2018 Apr; 200(8):2860-2868. PubMed ID: 29507106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The MHC Class I Cancer-Associated Neoepitope Trh4 Linked with Impaired Peptide Processing Induces a Unique Noncanonical TCR Conformer.
    Hafstrand I; Doorduijn EM; Duru AD; Buratto J; Oliveira CC; Sandalova T; van Hall T; Achour A
    J Immunol; 2016 Mar; 196(5):2327-34. PubMed ID: 26800871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors.
    Doorduijn EM; Sluijter M; Querido BJ; Oliveira CC; Achour A; Ossendorp F; van der Burg SH; van Hall T
    J Clin Invest; 2016 Feb; 126(2):784-94. PubMed ID: 26784543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proline substitution independently enhances H-2D(b) complex stabilization and TCR recognition of melanoma-associated peptides.
    Uchtenhagen H; Abualrous ET; Stahl E; Allerbring EB; Sluijter M; Zacharias M; Sandalova T; van Hall T; Springer S; Nygren PÅ; Achour A
    Eur J Immunol; 2013 Nov; 43(11):3051-60. PubMed ID: 23939911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100.
    van Stipdonk MJ; Badia-Martinez D; Sluijter M; Offringa R; van Hall T; Achour A
    Cancer Res; 2009 Oct; 69(19):7784-92. PubMed ID: 19789338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural and kinetic basis for heightened immunogenicity of T cell vaccines.
    Chen JL; Stewart-Jones G; Bossi G; Lissin NM; Wooldridge L; Choi EM; Held G; Dunbar PR; Esnouf RM; Sami M; Boulter JM; Rizkallah P; Renner C; Sewell A; van der Merwe PA; Jakobsen BK; Griffiths G; Jones EY; Cerundolo V
    J Exp Med; 2005 Apr; 201(8):1243-55. PubMed ID: 15837811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination.
    Chambers B; Grufman P; Fredriksson V; Andersson K; Roseboom M; Laban S; Camps M; Wolpert EZ; Wiertz EJ; Offringa R; Ljunggren HG; van Hall T
    Cancer Res; 2007 Sep; 67(18):8450-5. PubMed ID: 17875682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
    Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
    Front Immunol; 2019; 10():1505. PubMed ID: 31333652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TAP-ing into TIEPPs for cancer immunotherapy.
    Kiessling R
    J Clin Invest; 2016 Feb; 126(2):480-2. PubMed ID: 26784539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of the murine H-2D(b) and human HLA-A*0201 MHC class I-restricted HPV6 E7-specific cytotoxic T lymphocyte epitopes.
    Peng S; Mattox A; Best SR; Barbu AM; Burns JA; Akpeng B; Jeang J; Yang B; Ishida E; Hung CF; Wu TC; Pai SI
    Cancer Immunol Immunother; 2016 Mar; 65(3):261-71. PubMed ID: 26759151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide transporter TAP mediates between competing antigen sources generating distinct surface MHC class I peptide repertoires.
    Oliveira CC; Querido B; Sluijter M; Derbinski J; van der Burg SH; van Hall T
    Eur J Immunol; 2011 Nov; 41(11):3114-24. PubMed ID: 21898382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Going Pro to enhance T-cell immunogenicity: easy as π?
    Hickman HD; Yewdell JW
    Eur J Immunol; 2013 Nov; 43(11):2814-7. PubMed ID: 24155147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell determinants incorporating beta-amino acid residues are protease resistant and remain immunogenic in vivo.
    Webb AI; Dunstone MA; Williamson NA; Price JD; de Kauwe A; Chen W; Oakley A; Perlmutter P; McCluskey J; Aguilar MI; Rossjohn J; Purcell AW
    J Immunol; 2005 Sep; 175(6):3810-8. PubMed ID: 16148127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced major histocompatibility complex class I binding and immune responses through anchor modification of the non-canonical tumour-associated mucin 1-8 peptide.
    Lazoura E; Lodding J; Farrugia W; Ramsland PA; Stevens J; Wilson IA; Pietersz GA; Apostolopoulos V
    Immunology; 2006 Nov; 119(3):306-16. PubMed ID: 17067310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex.
    Slansky JE; Rattis FM; Boyd LF; Fahmy T; Jaffee EM; Schneck JP; Margulies DH; Pardoll DM
    Immunity; 2000 Oct; 13(4):529-38. PubMed ID: 11070171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dominant contribution of the proteasome and metalloproteinases to TAP-independent MHC-I peptide repertoire.
    Oliveira CC; Sluijter M; Querido B; Ossendorp F; van der Burg SH; van Hall T
    Mol Immunol; 2014 Nov; 62(1):129-36. PubMed ID: 24983205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective T Cell Responses Featured by Concordant Recognition of Middle East Respiratory Syndrome Coronavirus-Derived CD8+ T Cell Epitopes and Host MHC.
    Liu WJ; Lan J; Liu K; Deng Y; Yao Y; Wu S; Chen H; Bao L; Zhang H; Zhao M; Wang Q; Han L; Chai Y; Qi J; Zhao J; Meng S; Qin C; Gao GF; Tan W
    J Immunol; 2017 Jan; 198(2):873-882. PubMed ID: 27903740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
    LaTemple DC; Abrams JT; Zhang SY; Galili U
    Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class I
    Marijt KA; Doorduijn EM; van Hall T
    Mol Immunol; 2019 Sep; 113():43-49. PubMed ID: 29627136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A protective cytotoxic T cell response to a subdominant epitope is influenced by the stability of the MHC class I/peptide complex and the overall spectrum of viral peptides generated within infected cells.
    Gallimore A; Hombach J; Dumrese T; Rammensee HG; Zinkernagel RM; Hengartner H
    Eur J Immunol; 1998 Oct; 28(10):3301-11. PubMed ID: 9808199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.